2. Search Result
Search Result
Results for "

hemodynamic

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

4

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-11103
    Sitaxsentan sodium
    2 Publications Verification

    IPI 1040 sodium; TBC11251 sodium

    		 Endothelin Receptor TGF-β Receptor Cardiovascular Disease Metabolic Disease
    Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
    Sitaxsentan sodium
  • HY-160187
    AAA

    		Orphan GPCR Angiotensin Receptor Cardiovascular Disease
    AAA is an orally active 20-HETE receptor antagonist. AAA exerts antihypertensive and organoprotective effects. AAA blocks 20-HETE prohypertensive actions, suppresses intrarenal and circulating angiotensin II levels, and interferes with renin-angiotensin system interactions. AAA attenuates development of, and reverses established, ANG II (HY-13948)-dependent malignant hypertension. AAA reduces albuminuria, glomerulosclerosis, and cardiac hypertrophy linked to malignant hypertension. AAA can be used for the research of malignant hypertension .
    AAA
  • HY-113248
    3-Nitro-L-tyrosine

    		Endogenous Metabolite Adrenergic Receptor Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology
    3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis .
    3-Nitro-L-tyrosine
  • HY-113248S
    3-Nitro-L-tyrosine-d3

    		Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    3-Nitro-L-tyrosine-d3 is the deuterium labeled 3-Nitro-L-tyrosine (HY-113248). 3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis .
    3-Nitro-L-tyrosine-d3
  • HY-12184
    ONO-AE 248

    		Prostaglandin Receptor Endogenous Metabolite Cardiovascular Disease
    ONO-AE 248 is a selective EP3 receptor agonist with cardioprotective activity. ONO-AE 248 reduces myocardial infarction size by selectively binding to the EP3α receptor in mice. The cardioprotective effect of ONO-AE 248 is independent of hemodynamic effects. The mechanism of ONO-AE 248 may involve activation of protein kinase C and opening of K(ATP) channels .
    ONO-AE 248
  • HY-19259
    GP3269

    		Adenosine Kinase Neurological Disease
    GP3269 is a selective and orally active human adenosine kinase (AK) inhibitor with an IC50 of 11 nM against human adenosine kinase. GP3269 increases adenosine levels at epileptic foci, activates A1 receptors on excitatory neurons, and exhibits anticonvulsant activity in rats. GP3269 does not induce hemodynamic effects including changes in blood pressure or heart rate in rats. GP3269 can be used for epilepsy-related research .
    GP3269
  • HY-76520
    Sitaxsentan

    IPI 1040; TBC-11251

    		 Endothelin Receptor TGF-β Receptor Cardiovascular Disease Metabolic Disease
    Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
    Sitaxsentan
  • HY-114671
    Taprostene

    CG-4203

    		 Prostaglandin Receptor Cardiovascular Disease
    Taprostene (CG-4203) is a synthetic, chemically stable analogue of Prostacyclin (PGI2). Taprostene exhibits endothelium and myocardial protecting actions after acute myocardial ischemia and reperfusion in cats. Taprostene enhances cytoprotective actions, while minimizing unwanted hemodynamic effects .
    Taprostene
  • HY-113248R
    3-Nitro-L-tyrosine (Standard)

    		Endogenous Metabolite Reference Standards Cardiovascular Disease Inflammation/Immunology
    3-Nitro-L-tyrosine (Standard) is the analytical standard of 3-Nitro-L-tyrosine (HY-113248). This product is intended for research and analytical applications. 3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis .
    3-Nitro-L-tyrosine (Standard)
  • HY-160431
    8(9)-EET

    		PPAR NF-κB COX Drug Metabolite Metabolic Disease
    8(9)-EET is one of the main metabolites produced by the metabolism of arachidonic acid (HY-109590) through the cytochrome P450 epoxide pathway. 8(9)-EET is an effective substrate for COX-1 and COX-2. 8(9)-EET activates PPARα in HEK293 cells and inhibits the activity of NF-κB induced by IL-1β in a PPARα-dependent and -independent manner. The (8S,9R)-isomer of 8(9)-EET ([(8S,9R)-EET]) causes vasoconstriction, thereby reducing renal plasma flow and glomerular filtration rate .
    8(9)-EET
  • HY-A0300
    Cyclopeptide-5

    EMD 270179

    		 Integrin Cardiovascular Disease
    Cyclopeptide-5 (EMD 270179) is an αvβ3 antagonist that can improve PAF-induced increased adhesion of sickle red blood cells, capillary post-obstruction, and enhance blood flow dynamics. Cyclopeptide-5 also has cytotoxic effects .
    Cyclopeptide-5
  • HY-177326
    Ciprokiren

    Ro 44-9375

    		 Renin Cardiovascular Disease
    Ciprokiren (Ro 44-9375) is a Renin inhibitor with IC50s of 0.07 and 0.65 nM for hRenin in buffer and plasma, respectively. Ciprokiren be applied transdermally with similar hemodynamic effects without decrease of plasma renin activity or plasma immunoreactive angiotensin II. Ciprokiren has antihypertensive efficacy and can be used for hypertension research .
    Ciprokiren
  • HY-112072
    Ibopamine hydrochloride

    SB 7505 hydrochloride; SKF 100168 hydrochloride

    		 Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Ibopamine (SB 7505) hydrochloride is an orally active dopamine derivative. Ibopamine hydrochloride exerts agonistic effects on α, β adrenergic receptors and dopaminergic receptors. Ibopamine hydrochloride can be hydrolyzed to produce the active metabolite Epinine. Ibopamine hydrochloride possesses positive inotropic and vasodilatory effects, which can improve hemodynamics and renal function in heart failure models. Ibopamine hydrochloride has good safety profile and can be used in the research of diseases such as congestive heart failure .
    Ibopamine hydrochloride
  • HY-155517
    INF200

    		NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation .
    INF200
  • HY-108623
    Atizoram

    CP-80,633

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Atizoram (CP-80,633) is an orally active phosphodiesterase type 4 (PDE4) inhibitor. Atizoram blocks cAMP degradation, thereby increasing intracellular and plasma cAMP levels. Atizoram inhibits TNFα release. Atizoram can be used in research related to acute respiratory distress syndrome .
    Atizoram
  • HY-101045
    AT-112

    		Drug Derivative Cardiovascular Disease
    AT-112 is a ketotanserin analogue. AT-112 has hemodynamic effects. AT-112 significantly reduces portal vein branch blood flow and portal vein pressure. AT-112 can be used to study the pathogenesis of portal hypertension .
    AT-112
  • HY-117715
    CK-3197

    		Phosphodiesterase (PDE) Cardiovascular Disease
    CK-3197 is a weak inhibitor of Peak lll cyclic 3'5'-adenosine monophosphate phosphodiesterase (CAMP PDEl). CK-3197 has hemodynamic and myocardial energetic effects in vivo. CK-3197 is an imidazolone derivative used as a selective positive inotropic agent for congestive heart failure .
    CK-3197
  • HY-129714
    EMD 52297

    		Renin Metabolic Disease
    EMD 52297 is a Renin inhibitor, with acute hemodynamic and hormonal effects. EMD 52297 also acts as an ACE inhibitor .
    EMD 52297
  • HY-117358
    KW-5805

    		Others Inflammation/Immunology
    KW-5805 is an anti-ulcer agent that promotes the biosynthesis, storage and secretion of gastric mucus, improves gastric mucosal hemodynamics, and inhibits the decrease in gastric mucosal blood volume and mucosal oxygenation caused by steroid shock .
    KW-5805
  • HY-P10616
    Salusin-α

    		Endogenous Metabolite Cardiovascular Disease
    Salusin-α is an endogenous bioactive peptide with hemodynamic and cell proliferation activities. Salusin-α can stimulate the proliferation of quiescent vascular smooth muscle cells (VSMCs) and fibroblasts, leading to a rapid and significant decrease in blood pressure and heart rate, but its effect is weaker than that of Salusin-β (HY-P10617). Salusin-α has potential application value in cardiovascular disease research .
    Salusin-α
  • HY-115477
    Brilaroxazine hydrochloride

    RP5063 hydrochloride

    		 5-HT Receptor Cardiovascular Disease
    Brilaroxazine (RP5063) hydrochloride is a modulator of serotonin receptors, exhibiting potential therapeutic activity in the treatment of pulmonary arterial hypertension (PAH). Brilaroxazine hydrochloride has been shown to limit functional and structural changes associated with PAH, leading to significant improvements in pulmonary hemodynamics and right ventricular hypertrophy. Brilaroxazine hydrochloride also enhances oxygen saturation levels and alleviates elevated pulmonary arterial pressures when used as an adjunct to standard PAH therapies.
    Brilaroxazine hydrochloride
  • HY-P10617
    Salusin-β

    		Endogenous Metabolite Cardiovascular Disease
    Salusin-β is an endogenous bioactive peptide with significant hemodynamic and mitogenic activity. Salusin-β can stimulate the proliferation of quiescent vascular smooth muscle cells (VSMCs) and fibroblasts, leading to a rapid and significant decrease in blood pressure and heart rate. In addition, Salusin-β can stimulate the release of arginine vasopressin from the pituitary gland in rats. This makes Salusin-β have important application potential in cardiovascular disease research .
    Salusin-β
  • HY-W700639
    Tolafentrine

    		Phosphodiesterase (PDE) Neurological Disease
    Tolafentrine, a dual-selective phosphodiesterase 3/4 (PDE3/4) inhibitor, has been shown to have significant acute and chronic effects in a unilateral diacetamide-induced rat pulmonary hypertension model. Experiments show that long-term administration can significantly alleviate all unilateral bisacetamide-induced hemodynamic and gas exchange abnormalities, reduce right ventricular hypertrophy, and normalize pulmonary vascular remodeling changes .
    Tolafentrine
  • HY-178082
    MK-251

    		Others Cardiovascular Disease
    MK-251 is an orally active anti-arrhythmic agent. MK-251 prevents or modifies ventricular arrhythmias induced in dogs and baboons by tetrafluorethylbutylamine. MK-251 antagonizes the arrhythmias caused by Digoxin (HY-B1049) in cats. MK-251 at effective doses has little effect on basic cardiovascular parameters such as blood pressure, cardiac output, myocardial contractility and ventricular conduction, thus demonstrating its unique advantages .
    MK-251
  • HY-113248S1
    3-Nitro-L-tyrosine-13C6

    		Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    3-Nitro-L-tyrosine- 13C6 is the 13C labeled 3-Nitro-L-tyrosine (HY-113248). 3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis .
    3-Nitro-L-tyrosine-13C6
  • HY-121586
    Nafazatrom

    Bay g 6575

    		 Lipoxygenase Cardiovascular Disease
    Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro .
    Nafazatrom
  • HY-11103R
    Sitaxsentan sodium (Standard)

    IPI 1040 sodium (Standard); TBC11251 sodium (Standard)

    		 Endothelin Receptor Reference Standards TGF-β Receptor Cardiovascular Disease Metabolic Disease
    Sitaxsentan (sodium) (Standard) is the analytical standard of Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) (HY-11103). This product is intended for research and analytical applications. Sitaxsentan sodium is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
    Sitaxsentan sodium (Standard)
  • HY-76520S
    Sitaxsentan-13C6

    IPI 1040-13C6 ; TBC-11251-13C6

    		 Isotope-Labeled Compounds Endothelin Receptor TGF-β Receptor Cardiovascular Disease Metabolic Disease
    Sitaxsentan- 13C6 (IPI 1040- 13C6) is 13C labeled Sitaxsentan (HY-76520). Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
    Sitaxsentan-13C6
  • HY-114986
    6-Keto-PGE1
    1 Publications Verification

    6-keto-Prostaglandin E1

    		 β-glucuronidase Cardiovascular Disease
    6-Keto-PGE1 (6-keto-Prostaglandin E1) is a biologically active derivative of PGE1. 6-Keto-PGE1 inhibits adenosine diphosphate-induced platelet aggregation. 6-Keto-PGE1 reduces cardiac afterload, decreases the accumulation of plasma myocardial depressant factor (MDF), lowers arterial blood pressure, dilates vascular beds, inhibits the vasoconstrictive response of vascular smooth muscle, and increases pulmonary compliance. 6-Keto-PGE1 directly stabilizes isolated cat liver lysosomes and significantly reduces the release of β-glucuronidase and cathepsin D. 6-Keto-PGE1 prolongs the survival time of traumatized rats and exerts protective effects through hemodynamic and cytoprotective actions. 6-Keto-PGE1 reduces central airway resistance. 6-Keto-PGE1 can be used in studies related to traumatic shock .
    6-Keto-PGE1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: